Table 5 Deaths, serious adverse events, and adverse events leading to permanent discontinuation of study drug (safety population)
AEs, n (%) | Everolimus N  =  120 |
|---|---|
Patients with any AE(s) | 89 (74.2) |
 Death | 0 (0.0) |
 SAE(s) | 32 (26.7) |
 Discontinuation due to AE(s) a | 8 (6.7) |
 AE(s) causing dose adjustment or study drug interruption | 36 (30.0) |
 CTC Grade 3 or 4 | 28 (23.3) |
 Leading to hospitalization/prolonged hospitalization | 29 (24.2) |
 Suspected to be drug related | 62 (51.7) |